Mirus Bio Overview
- Year Founded
-
1995
- Status
-
Acquired/Merged
- Employees
-
60
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
Mirus Bio General Information
Description
Provider of gene transfer technologies intended to serve the pharmaceutical industry. The company focuses on the discovery and development of innovative nucleic acid-based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform, thereby offering life scientists with advanced tools for gene expression, biotherapeutic protein production, virus manufacturing and genome editing.
Contact Information
Website
www.mirusbio.com(Operating Subsidiary)
Corporate Office
- 5602 Research Park Boulevard
- Suite 210
- Madison, WI 53719
- United States
Corporate Office
- 5602 Research Park Boulevard
- Suite 210
- Madison, WI 53719
- United States
Mirus Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mirus Bio Comparisons
Industry
Financing
Details
Mirus Bio Competitors (44)
One of Mirus Bio’s 44 competitors is ToolGen, a Formerly VC-backed company based in Seoul, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ToolGen | Formerly VC-backed | Seoul, South Korea | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| Horizon Discovery | Formerly VC-backed | Cambridge, United Kingdom |
Mirus Bio Patents
Mirus Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026117673-A1 | Transfection compositions comprising cationic polymers, cationic lipids, and stabilizing agents | Pending | 30-Nov-2024 | ||
| WO-2026076376-A1 | Transfection reagent comprising cationic polymer and amphipathic compound | Pending | 06-Oct-2024 | ||
| JP-2026517819-A | Small molecule enhancer for adeno-associated virus production | Pending | 02-May-2023 | ||
| AU-2024265723-A1 | Small molecule enhancers for adeno-associated virus production | Pending | 02-May-2023 | ||
| EP-4705491-A2 | Small molecule enhancers for adeno-associated virus production | Pending | 02-May-2023 | C12N15/86 |
Mirus Bio Signals
Mirus Bio Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mirus Bio FAQs
-
When was Mirus Bio founded?
Mirus Bio was founded in 1995.
-
Where is Mirus Bio headquartered?
Mirus Bio is headquartered in Madison, WI.
-
What is the size of Mirus Bio?
Mirus Bio has 60 total employees.
-
What industry is Mirus Bio in?
Mirus Bio’s primary industry is Biotechnology.
-
Is Mirus Bio a private or public company?
Mirus Bio is a Private company.
-
What is the current valuation of Mirus Bio?
The current valuation of Mirus Bio is .
-
What is Mirus Bio’s current revenue?
The current revenue for Mirus Bio is .
-
Who are Mirus Bio’s investors?
Gamma Biosciences and Roche have invested in Mirus Bio.
-
Who are Mirus Bio’s competitors?
ToolGen, Editas Medicine, Regenxbio, Cytovance Biologics, and Horizon Discovery are some of the 44 competitors of Mirus Bio.
-
When was Mirus Bio acquired?
Mirus Bio was acquired on 31-Jul-2024.
-
Who acquired Mirus Bio?
Mirus Bio was acquired by Merck.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process